Kratom Research 2025/2026: Where Do We Stand?

What We Know with High Confidence

Mitragynine is the main alkaloid, typically up to 66% of the alkaloid content
7-hydroxymitragynine occurs in small amounts and shows higher μ-MOR affinity than mitragynine
Both alkaloids are partial agonists at the μ-opioid receptor in preclinical models
Mitragynine is metabolized in the liver via CYP enzymes
Kratom has dependence potential – withdrawal symptoms after regular use are documented

What We Know with Moderate Confidence

Kratom reduces classical opioid withdrawal symptoms in animal models
Self-report surveys: a considerable share of users report using kratom for opioid cessation
Alkaloid profiles vary considerably by origin, harvest and processing
Heavy metal and pesticide contamination is a documented quality problem

What We Do Not Know (Research Gaps)

Safe limits in humans – no clinically validated thresholds
Long-term consequences of regular kratom use
Whether kratom is clinically effective and safe as substitution therapy (RCTs missing)
The complete interaction profile with other medications
Whether and to what extent kratom is hepatotoxic

Ongoing and Planned Research

Johns Hopkins University has been carrying out kratom research for several years – surveys, case reports, preclinical work. The difficulty: kratom is not scheduled, but neither is it officially recognized as a research substance. That makes funding and controlled clinical trials harder to obtain.

Conclusion

Kratom research has developed, but remains far behind what would be needed for well-founded health policy decisions. The research deficit is in part the result of political blockades. Kratom deserves more serious research, not less.

Legal notice

This article is for informational purposes only and does not constitute legal advice. Its content is not intended to encourage consumption. Laws may change; the applicable regulations and information from official bodies are authoritative. Image source: https://www.kratoein.com/

Back to blog